Erica N. Heying

Intertumoral Heterogeneity of CD3+ and CD8+ T-Cell Densities in the Microenvironment of DNA Mismatch-Repair–Deficient Colon Cancers: Implications for Prognosis

Michael Barnes, Azita Djalilvand, S. Alberts, 2018, Clinical Cancer Research.

CD3+ and CD8+ tumor-infiltrating lymphocyte (TIL) densities to prognostically stratify DNA mismatch repair-deficient (dMMR) colon cancer patients (pts): NCCTG N0147 (Alliance).

Michael Barnes, Azita Djalilvand, S. Alberts, 2018 .

Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy: NCCTG N0147 (Alliance).

D. Sargent, R. Goldberg, A. Shields, 2017 .

Prognostic utility of immune markers and validation of Immunoscore in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance).

D. Sargent, J. Galon, A. Shields, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance).

D. Sargent, A. Benson, J. Galon, 2018 .

Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance).

D. Sargent, A. Benson, J. Galon, 2017 .

Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance]).

Tsung-Teh Wu, D. Wigle, S. Alberts, 2021, European journal of cancer.

Pre-Emptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial.

J. Sloan, B. Pasche, M. Lacouture, 2021, The oncologist.

Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.

Afsaneh Barzi, Katrina Pedersen, Jeannine S McCune, 2019, The Lancet. Oncology.